SCHEMBL15077835

SCHEMBL15077835

CCOC(=O)c1ccnc(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 3/20 0.46
MKNK2 Q9HBH9 1/20 0.46
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
PIK3CA P42336 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
ATR Q13535 1/20 0.43
HTT P42858 1/20 0.43
SYK P43405 1/20 0.42
LMNA P02545 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM5A P29375 1/20 0.42
KDM5C P41229 1/20 0.42
KDM4C Q9H3R0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29640073 0.87 ATR (0.53) JMJD6L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL14359967 0.87 ATR (0.53) JMJD6L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL29867423 0.83 NPC1 (0.39) MKNK2ALDH1A1GAAL3MBTL1NPC1
SCHEMBL29465812 0.82 KDM4D (0.47) ALDH1A1ATRKDM4EMAPTKDM5A
SCHEMBL29626657 0.82 CYP17A1 (0.46) ATRMAPTCA12CA1CA9
SCHEMBL6935872 0.82 JMJD6 (0.51) JMJD6NPC1RAB9APIK3CASMN1; SMN2
SCHEMBL2080457 0.82 KDM4D (0.47) ALDH1A1ATRKDM4EMAPTKDM5A
SCHEMBL6177797 0.82 CYP17A1 (0.46) ATRMAPTCA12CA1CA9
SCHEMBL25657241 0.82 ACACB (0.43) NPC1RAB9ASMN1; SMN2PKMATR
SCHEMBL15354529 0.81 RIOK2 (0.50) PKMATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760838-B1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARM SPA (IT) 2017-05-10 EP disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 JMJD6 771/4885MKNK2 60/4885ALDH1A1 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.